SLFN11 and PD-L1 have been chosen since they have been in the limelight of colorectal cancer research in recent years, with an essential role as immunological checkpoints and potential therapeutical targets as well as biomarkers for response and prediction of therapy outcomes. The gene discussed is CD274; the disease is colorectal cancer.